Pollens - grasses, sweet vernal grass anthoxanthum odoratum - Biologic Drug Details

Summary for pollens - grasses, sweet vernal grass anthoxanthum odoratum

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - grasses, sweet vernal grass anthoxanthum odoratum

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - grasses, sweet vernal grass anthoxanthum odoratum Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - grasses, sweet vernal grass anthoxanthum odoratum Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - grasses, sweet vernal grass anthoxanthum odoratum Derived from Patent Text Search

No patents found based on company disclosures

Pollens - grasses, sweet vernal grass anthoxanthum odoratum Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Biologic Drugs: Pollens - Grasses, Sweet Vernal Grass (Anthoxanthum odoratum)

Introduction

The biologics market, which includes treatments for allergies such as those caused by grass pollens, is experiencing significant growth driven by various factors. This article will delve into the market dynamics and financial trajectory of biologic drugs, particularly those targeting allergies to sweet vernal grass (Anthoxanthum odoratum).

Biologics Market Overview

The global biologics market is projected to reach USD 699.5 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.8% from 2024 to 2032. This growth is fueled by the increasing prevalence of chronic diseases, technological advancements, and the rising adoption of biosimilars[1][4].

Drivers of the Biologics Market

Several key factors are driving the growth of the biologics market:

Increasing Burden of Chronic Diseases

The rising incidence of chronic diseases, including allergic conditions like allergic rhinitis and asthma, is a significant driver. Sweet vernal grass pollen is a common allergen that triggers these conditions, making biologic treatments increasingly necessary[1][4].

Technological Advancements

Continuous technological advancements are facilitating the development of more targeted and effective therapies. This includes improved drug delivery systems and the creation of more precise allergenic extracts like those used in immunotherapy products such as ORALAIR[1].

Growing Adoption of Biosimilars

Biosimilars, which are biologic products that are highly similar to an already approved biologic drug, are gaining traction due to their cost-effectiveness and similar efficacy. This trend is expected to continue, contributing to the market's growth[4].

Improved Healthcare Infrastructure

Enhanced healthcare infrastructure and increasing awareness about biologic therapies are also driving the market forward. Better diagnostic capabilities and treatment options are making biologics more accessible and appealing to patients and healthcare providers[1].

Market Segments Relevant to Grass Pollen Allergies

Allergenic Extracts

Allergenic extracts, such as those from sweet vernal grass (Anthoxanthum odoratum), are used in immunotherapy products. These extracts are part of a broader market for allergenics, which is a subset of the biologics market. Products like ORALAIR, which include Anthoxanthum odoratum, are approved for use in treating grass pollen-induced allergic rhinitis[2].

Immunotherapy Market

The immunotherapy market, which includes treatments for allergies, is still relatively underdeveloped but growing. For instance, the allergy immunotherapy (AIT) market represents about 12% of the global allergic rhinitis market, valued at approximately €1 billion[3].

Financial Trajectory

Current Market Size

The biologics market, including segments relevant to grass pollen allergies, was valued at USD 349.6 billion in 2023. This figure is expected to more than double by 2032, reaching USD 699.5 billion[1].

Growth Projections

The biosimilar and biologics market, which encompasses treatments for allergies, is projected to reach USD 1,060.7 billion by 2034, growing at a CAGR of 7.6% from 2024 to 2034. The segment related to allergenic extracts and immunotherapy is expected to contribute significantly to this growth[4].

Regional Market Performance

North America currently holds a substantial value share of the biologics market, with 43.8% in 2023. However, regions like China and India are expected to exhibit high growth rates, with China's market growing at a CAGR of 8.8% and India's at 8.5% from 2024 to 2034[4].

Key Players and Strategies

Stallergenes Greer

Companies like Stallergenes Greer are focusing on expanding their portfolio of treatment solutions, including injectable and oral forms of allergen extracts. They aim to maintain a robust financial position and invest in clinical and regulatory domains to stay competitive[3].

Product Development and Innovation

Manufacturers are investing heavily in process development, optimization, and quality assurance to improve the production of biologics and biosimilars. This expertise is crucial for enhancing the manufacturing process and ensuring the quality of these complex biological products[4].

Challenges and Opportunities

Regulatory Approvals

One of the key challenges facing companies in this market is the complex and costly process of obtaining regulatory approvals. However, the escalating approvals of biologics by regulatory agencies also present opportunities for growth[1].

Clinical and Regulatory Domains

Ensuring that every employee embraces the transformation and remains driven by the company's vision is crucial. Companies must focus on clinical and regulatory efforts to develop new allergen references and maintain market leadership[3].

Allergenic Extracts: Sweet Vernal Grass (Anthoxanthum odoratum)

Characteristics and Distribution

Sweet vernal grass (Anthoxanthum odoratum) is a fragrant, perennial grass that thrives in various habitats, including wetlands, forests, and dry grasslands. It is a significant allergen source, particularly during the spring season when it pollinates[5].

Clinical Implications

Individuals allergic to sweet vernal grass pollen may experience symptoms like allergic rhinitis and asthma. The major allergenic component of sweet vernal grass is Ant o 1, and cross-reactivity is evident within the Pooidae subfamily, which includes other grasses[5].

Conclusion

The biologics market, particularly the segment focused on grass pollen allergies like those caused by sweet vernal grass (Anthoxanthum odoratum), is poised for significant growth. Driven by technological advancements, increasing chronic disease prevalence, and the adoption of biosimilars, this market is expected to continue its upward trajectory.

Key Takeaways

• The biologics market is projected to reach USD 699.5 billion by 2032.
• The growing incidence of chronic diseases and technological advancements are key drivers.
• Biosimilars are gaining traction due to their cost-effectiveness.
• The immunotherapy market, including treatments for grass pollen allergies, is growing but still underdeveloped.
• Regional markets like China and India are expected to exhibit high growth rates.

FAQs

What is the projected growth rate of the biologics market from 2024 to 2032?

The biologics market is expected to grow at a CAGR of 7.8% from 2024 to 2032[1].

What are the main drivers of the biologics market?

The main drivers include the increasing prevalence of chronic diseases, technological advancements, and the growing adoption of biosimilars[1][4].

What is the significance of sweet vernal grass (Anthoxanthum odoratum) in the biologics market?

Sweet vernal grass is a significant allergen source used in immunotherapy products like ORALAIR to treat grass pollen-induced allergic rhinitis[2].

How is the immunotherapy market performing?

The immunotherapy market, which includes treatments for allergies, is growing but still relatively underdeveloped, representing about 12% of the global allergic rhinitis market[3].

Which regions are expected to show high growth rates in the biologics market?

China and India are expected to exhibit high growth rates, with China's market growing at a CAGR of 8.8% and India's at 8.5% from 2024 to 2034[4].

Sources

1. Biologics Market Size to Reach USD 699.5 Billion by 2032, Impelled by Emergence of Advanced Drug Delivery Systems. Biospace.
2. Anthoxanthum odoratum: Uses, Interactions, Mechanism of Action. DrugBank.
3. Company Report 2019 - Stallergenes Greer. Stallergenes Greer.
4. Biosimilar and Biologics Market Is Expected to Reach USD 1,060.7 Billion by 2034 and Grow at a Compound Annual Growth Rate of 7.6% - FMI Inc.. GlobeNewswire.
5. g1 Sweet vernal grass | Thermo Fisher Scientific. Thermo Fisher Scientific.